Here's a recap of recent blog posts and other news.
After a great deal of work, we are pleased to announce details of two new publications, which are linked to from this
RxISK blog post.
1. A paper in the International
Journal of Risk & Safety in Medicine, entitled
Enduring sexual dysfunction after treatment with antidepressants: 300 cases.
In 2014, we were the first group to publish details in the medical literature about persistent sexual dysfunction after using isotretinoin. Our new paper once again includes this problem. In fact, isotretinoin was the single most commonly reported drug in our study.
2. We have also put together a
petition to the FDA requesting changes to SSRI and SNRI product labels to warn about post-SSRI sexual dysfunction and persistent genital arousal disorder. The petition sets out in detail the nature of the problem, the history of the conditions, and what needs to be done about it.
In case you missed it, see the The New York Times article Many People Taking Antidepressants Discover They Cannot Quit,
which quotes RxISK's Dr. Derelie Mangin:
"The truth is that the state of the science is absolutely inadequate... We don't have enough information about what antidepressant withdrawal entails, so we can't design proper tapering approaches."
Thank you for your support.
Your feedback, as always, is greatly appreciated.
David Healy, MD
|
